Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2017 Jun;114:114-130. doi: 10.1016/j.critrevonc.2017.04.004. Epub 2017 Apr 6.

Vincristine-induced peripheral neuropathy in children with cancer: A systematic review.

Author information

1
Department of Pediatric Hematology/Oncology, VU University Medical Center Amsterdam, Postbus 7057, 1007, MB, Amsterdam, The Netherlands. Electronic address: mi.vandevelde@vumc.nl.
2
Department of Pediatric Hematology/Oncology, VU University Medical Center Amsterdam, Postbus 7057, 1007, MB, Amsterdam, The Netherlands; Academy, Princess Máxima Center for Pediatric Oncology Utrecht, Lundlaan 6, Utrecht, The Netherlands.
3
Department of Pediatric Hematology/Oncology, VU University Medical Center Amsterdam, Postbus 7057, 1007, MB, Amsterdam, The Netherlands.
4
Department of Clinical Pharmacology, VU University Medical Center Amsterdam, Postbus 7057, 1007, MB, Amsterdam, The Netherlands.
5
Medical Library, VU University Amsterdam, Postbus 7057, 1007, MB, Amsterdam, The Netherlands.

Abstract

Vincristine-induced peripheral neuropathy (VIPN) is a dose-limiting side effect of vincristine (VCR) treatment in children, leading to diminished quality of life. Much remains unknown about the underlying mechanisms of VIPN. This review systematically summarizes the available literature concerning contributing factors of VIPN development in children. Studied factors include patient characteristics, VCR dose, administration method, pharmacokinetics, and genetic factors. Furthermore, this review reports on currently available tools to assess VIPN in children. In total, twenty-eight publications were included. Results indicate that Caucasian race, higher VCR dose, older age and low clearance negatively influence VIPN, although results regarding the latter two factors were rather conflicting. Moreover, genetic pathways influencing VIPN were identified. Furthermore, the studied tools to assess VIPN seriously impairs comparability across study results. Studying the factors and their interactions that seem to influence VIPN in children, should aid in personalized VCR treatment, thereby increasing VCR effectiveness while minimizing toxicity.

KEYWORDS:

Chemotherapeutic; Neurotoxicity; Oncology; Pediatrics; Peripheral neuropathy; Vincristine

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center